ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs

Dik J. Kwekkeboom, Eric P. Krenning, Rachida Lebtahi, Paul Komminoth, Beata Kos-Kudła, Wouter W. De Herder, Ursula Plöckinger, Göran Åkerström, Bruno Annibale, Rudolf Arnold, Emilio Bajetta, Jaroslava Barkmanova, Yuan Jia Chen, Frederico Costa, Anne Couvelard, Joseph Davar, Gianfranco Delle Fave, Barbro Eriksson, Massimo Falconi, Diego FeroneDavid Gross, Ashley Grossman, Björn Gustafsson, Rudolf Hyrdel, Diana Ivan, Gregory Kaltsas, Reza Kianmanesh, Günter Klöppel, Ulrich Peter Knigge, Val Lewington, Anne Marie McNicol, Emmanuel Mitry, Ola Nilsson, Kjell Öberg, Juan O'Connor, Dermot O'Toole, Ulrich Frank Pape, Mauro Papotti, Marianne Pavel, Aurel Perren, Marco Platania, Guido Rindi, Philippe Ruszniewski, Ramon Salazar, Aldo Scarpa, Klemens Scheidhauer, Jean Yves Scoazec, Anders Sundin, Waldemar Szpak, Babs Taal, Pavel Vitek, Marie Pierre Vullierme, Bertram Wiedenmann

Research output: Contribution to journalArticle

Abstract

The purpose of this guideline is to assist physicians caring for patients with neuroendocrine tumors in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT), and in defining the minimum requirements for PRRT. This guideline also makes recommendations on what minimal patient, tumor, and treatment outcome characteristics should be reported for PRRT in order to make comparisons between studies possible. It is not this guideline's aim to give specific recommendations on the use of specific radiolabeled somatostatin analogs for PRRT because different analogs are being used, and their availability depends on national law and local permissions.

Original languageEnglish
Pages (from-to)220-226
Number of pages7
JournalNeuroendocrinology
Volume90
Issue number2
DOIs
Publication statusPublished - Aug 2009

Keywords

  • Carcinoids
  • GEPNET
  • Neuroendocrine tumors
  • Radiolabeled somatostatin analogues

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Endocrine and Autonomic Systems
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs'. Together they form a unique fingerprint.

  • Cite this

    Kwekkeboom, D. J., Krenning, E. P., Lebtahi, R., Komminoth, P., Kos-Kudła, B., De Herder, W. W., Plöckinger, U., Åkerström, G., Annibale, B., Arnold, R., Bajetta, E., Barkmanova, J., Chen, Y. J., Costa, F., Couvelard, A., Davar, J., Delle Fave, G., Eriksson, B., Falconi, M., ... Wiedenmann, B. (2009). ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology, 90(2), 220-226. https://doi.org/10.1159/000225951